Tissue Factor and Protease-Activated Receptor Signaling in Cancer

Florence Schaffner; Wolfram Ruf

doi:10.1055/s-2008-1079254

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2008; 34(2): 147-153
DOI: 10.1055/s-2008-1079254

Tissue Factor and Protease-Activated Receptor Signaling in Cancer

Florence Schaffner¹ ^, ³ , Wolfram Ruf² ^, ³

¹Research Associate
²Professor
³Department of Immunology, The Scripps Research Institute, La Jolla, California

Abstract

ABSTRACT

The activation of the coagulation cascade in the tumor microenvironment is a key feature of advanced malignancies. On tumor cells, tissue factor (TF) plays a central role to initiate cross-talk through the release of procoagulant microparticles or through direct, protease-activated receptor (PAR)-mediated cell signaling that leads to the production of soluble cytokines and angiogenic growth factors. In addition, the hemostatic system in the host compartment sustains crucial circuits that promote metastasis and support tumor growth and angiogenesis. Experimental tumor and genetic models have defined specific pathways that are supported by tumor cell and host TF and have identified potential therapeutic modalities to specifically interrupt TF signaling in tumor biology without impairment of hemostatic functions.

KEYWORDS

Tissue factor - breast cancer - coagulation - protease-activated receptors - angiogenesis

Volltext

Referenzen

REFERENCES

1 Rickles F R, Patierno S, Fernandez P M. Tissue factor, thrombin, and cancer. Chest. 2003; 124(3 Suppl) 58S-68S
2 Clauss M, Gerlach M, Gerlach H et al.. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990; 172 1535-1545
3 Shoji M, Hancock W W, Abe K et al.. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 1998; 152 399-411
4 Ruf W, Mueller B M. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost. 2006; 32(Suppl 1) 61-68
5 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000; 342 1953-1958
6 Dvorak H F, Quay S C, Orenstein N S et al.. Tumor shedding and coagulation. Science. 1981; 212 923-924
7 Hron G, Kollars M, Weber H et al.. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007; 97 119-123
8 Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110 1723-1729
9 Chand H S, Ness S A, Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. Int J Cancer. 2006; 118 1713-1720
10 Bogdanov V Y, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003; 9 458-462
11 Bogdanov V Y, Kirk R I, Miller C et al.. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost. 2006; 4 158-167
12 Yu J L, Rak J W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004; 2 2065-2067
13 Grimstad I A, Prydz H. Thromboplastin release,but not content,correlates with spontaneous metastasis of cancer cells. Int J Cancer. 1988; 41 427-431
14 Milsom C, Anderson G M, Weitz J I, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost. 2007; 5 2550-2552
15 Sahni A, Simpson-Haidaris P J, Sahni S K, Vaday G G, Francis C W. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost. 2008; 6 176-183
16 Coughlin S R. Thrombin signalling and protease-activated receptors. Nature. 2000; 407 258-264
17 D'Andrea M R, Derian C K, Santulli R J, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol. 2001; 158 2031-2041
18 Smadja D M, Bieche I, Uzan G et al.. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system. Arterioscler Thromb Vasc Biol. 2005; 25 2321-2327
19 Kisucka J, Butterfield C E, Duda D G et al.. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006; 103 855-860
20 Camerer E, Qazi A A, Duong D N, Cornelissen I, Advincula R, Coughlin S R. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004; 104 397-401
21 Rao L V, Pendurthi U R. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005; 25 47-56
22 Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol. 2005; 25 1545-1550
23 Ahamed J, Versteeg H H, Kerver M et al.. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A. 2006; 103 13932-13937
24 Mueller B M, Reisfeld R A, Edgington T S, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992; 89 11832-11836
25 Nierodzik M L, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10 355-362
26 Mueller B M, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis. J Clin Invest. 1998; 101 1372-1378
27 Bromberg M E, Konigsberg W H, Madison J F, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995; 92 8205-8209
28 Palumbo J S, Talmage K E, Massari J V et al.. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood. 2007; 110 133-141
29 Wang H, Fu W, Im J H et al.. Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol. 2004; 164 935-941
30 Radjabi A R, Sawada K, Jagadeeswaran S et al.. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and {beta}1-integrin on the cell surface. J Biol Chem. 2008; 283 2822-2834
31 Shi X, Gangadharan B, Brass L F, Ruf W, Mueller B M. Protease-activated receptor 1 (PAR1) and PAR2 contribute to tumor cell motility and metastasis. Mol Cancer Res. 2004; 2 395-402
32 Camerer E, Duong D N, Hamilton J R, Coughlin S R. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood. 2004; 103 152-154
33 Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Crosstalk of integrin α3β1 and tissue factor in cell migration. Mol Biol Cell. 2004; 15 4416-4425
34 Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem. 2004; 279 23038-23044
35 Ott I, Weigand B, Michl R et al.. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation. 2005; 111 349-355
36 Ahamed J, Niessen F, Kurokawa T et al.. Regulation of macrophage procoagulant responses by the tissue factor cytoplasmic domain in endotoxemia. Blood. 2007; 109 5251-5259
37 Siegbahn A, Johnell M, Sørensen B B, Petersen L C, Heldin C H. Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thromb Haemost. 2005; 93 27-34
38 Versteeg H H, Schaffner F, Kerver M et al.. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008; 111 190-199
39 Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost. 2003; 1 1495-1503
40 Morris D R, Ding Y, Ricks T K, Gullapalli A, Wolfe B L, Trejo J. Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006; 66 307-314
41 Hjortoe G M, Petersen L C, Albrektsen T et al.. Tissue factor-factor VIIa specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated via PAR-2 and results in increased cell migration. Blood. 2004; 103 3029-3037
42 Zoudilova M, Kumar P, Ge L, Wang P, Bokoch G M, DeFea K A. Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem. 2007; 282 20634-20646
43 Koizume S, Jin M-S, Miyagi E et al.. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res. 2006; 66 9453-9460
44 Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. 2001; 61 5933-5940
45 Sorensen B B, Rao L VM, Tornehave D, Gammeltoft S, Petersen L C. Anti-apoptotic effect of coagulation factor VIIa. Blood. 2003; 102 1708-1715
46 Versteeg H H, Arnold S C, Richel D J, Peppelenbosch M P. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene. 2004; 23 410-417
47 Pendurthi U R, Allen K E, Ezban M, Rao L VM. Factor VIIa and thrombin induce the expression of cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa tissue factor-induced signal transduction. J Biol Chem. 2000; 275 14632-14641
48 Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem. 2000; 275 6580-6585
49 Liu Y, Mueller B M. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun. 2006; 344 1263-1270
50 Albrektsen T, Sorensen B B, Hjortoe G M, Fleckner J, Rao L VM, Petersen L C. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007; 5 1588-1597
51 Uusitalo-Jarvinen H, Kurokawa T, Mueller B M, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007; 27 1456-1462
52 Palumbo J S, Kombrinck K W, Drew A F et al.. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000; 96 3302-3309
53 Belting M, Dorrell M I, Sandgren S et al.. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004; 10 502-509
54 Griffin C T, Srinavasan Y, Zheng Y-W, Huang W, Coughlin S R. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 2001; 293 1666-1670
55 Caunt M, Huang Y Q, Brooks P C, Karpatkin S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J Thromb Haemost. 2003; 1 2097-2102
56 Haralabopoulos G C, Grant D S, Kleinman H K, Maragoudakis M E. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am J Physiol. 1997; 273 C239-C245
57 Zania P, Kritikou S, Flordellis C S, Maragoudakis M E, Tsopanoglou N E. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1 (PAR-1): association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther. 2006; 318 246-254
58 Colognato R, Slupsky J R, Jendrach M, Burysek L, Syrovets T, Simmet T. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood. 2003; 102 2645-2652
59 Fields R C, Schoenecker J G, Hart J P, Hoffman M R, Pizzo S V, Lawson J H. Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol. 2003; 162 1817-1822
60 Csernok E, Ai M, Gross W L et al.. Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood. 2006; 107 4440-4448
61 Rafii D C, Psaila B, Butler J, Jin D K, Lyden D. Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells. Arterioscler Thromb Vasc Biol. 2008; 28 217-222
62 Zhang Y, Deng Y, Luther T et al.. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994; 94 1320-1327
63 Kakkar A K, Chinswangwatanakul V, Lemoine N R, Tebbutt S, Williamson R CN. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg. 1999; 86 890-894
64 Abe K, Shoji M, Chen J et al.. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A. 1999; 96 8663-8668
65 Yu J L, May L, Lhotak V et al.. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005; 105 1734-1741
66 Yin Y J, Salah Z, Grisaru-Granovsky S et al.. Human protease-activated receptor 1 expression in malignant epithelia. A role in invasiveness. Arterioscler Thromb Vasc Biol. 2003; 23 940-944
67 Martin C B, Mahon G, Klinger M et al.. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene. 2001; 20 1953-1963
68 Yin Y J, Katz V, Salah Z et al.. Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization. Cancer Res. 2006; 66 5224-5233
69 Gupta G P, Nguyen D X, Chiang A C et al.. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007; 446 765-770
70 Caunt M, Hu L, Tang T, Brooks P C, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res. 2006; 66 4125-4132
71 Miller G J, Bauer K A, Howarth D J, Cooper J A, Humphries S E, Rosenberg R D. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004; 2 2107-2114
72 Zacharski L R, Henderson W G, Rickles F R et al.. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer. 1984; 53 2046-2052
73 Klerk C P, Smorenburg S M, Otten H M et al.. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23 2130-2135
74 Kakkar A K, Levine M N, Kadziola Z et al.. Low molecular weight heparin. therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol. 2004; 22 1944-1948
75 Lee A YY, Rickles F R, Julian J A et al.. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 23 2123-2129
76 Hembrough T A, Swartz G M, Papathanassiu A et al.. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003; 63 2997-3000

Wolfram RufM.D.

Department of Immunology, SP258, The Scripps Research Institute

10550 North Torrey Pines Road, La Jolla, CA 92037

eMail: ruf@scripps.edu